Advertisement

Arrhythmia Induction in Children

  • Nikola Krmek
Chapter

Abstract

In this chapter we will demonstrate that medication administration in children for arrhythmia induction has specific characteristics. Basic principles such as pharmacology and mechanism of action are mostly the same as in adults, and the biggest difference is in dosing. It goes without saying that there are not many studies performed in children as in adults and many of dosing schemes are based on the particular experience of different electrophysiology centers. The current practice for selecting the pediatric dose for the drugs used in electrophysiology does not guarantee a safe and effective dose for children. Reducing the dose used in adults by formulas using age, body weight, or any other demographic variable without any prior evidence of how these factors contribute to the drug’s plasma concentration may lead to unreliable pediatric dose estimates. However, this practice is universally used in electrophysiology for medication that induces arrhythmias in children as in adults. Although it is relatively easy and simple to use empirical doses for these drugs, growth and development of the child can result in unpredictable dose-effect pharmacokinetic changes. Recent advances in qualitative and quantitative pharmacokinetic analysis will allow electrophysiologists to determine the most appropriate dose for the child that needs ablation. Until then, we should use the doses published by pediatric electrophysiology teams in various articles dealing with pediatric catheter ablation. These doses will be listed in the following paragraphs.

References

  1. 1.
    Gautam NK, Rafique MB, Numan MT. Impact of isoproterenol infusion on BIS and metabolic values in pediatric patients undergoing electrophysiology studies. J Clin Anesth. 2014;26:611–5.CrossRefGoogle Scholar
  2. 2.
    Moore JP, Kannankeril PJ, Fish FA. Isoproterenol administration during general anesthesia for the evaluation of children with ventricular preexcitation. Circ Arrhythm Electrophysiol. 2011;4:73–8.CrossRefGoogle Scholar
  3. 3.
    Isuprel (isoproterenol) [prescribing information]. Lake Forest, IL: Hospira, Inc.; 2013.Google Scholar
  4. 4.
    Kubuš P, Vít P, Gebauer RA, Materna O, Janoušek J. Electrophysiologic profile and results of invasive risk stratification in asymptomatic children and adolescents with the Wolff-Parkinson-white electrocardiographic pattern. Circ Arrhythm Electrophysiol. 2014;7:218–23.CrossRefGoogle Scholar
  5. 5.
    Liberman L, Hordof AJ, Fishberger SB, Pass RH. The role of isoproterenol testing following radiofrequency catheter ablation of accessory pathways in children. Pacing Clin Electrophysiol. 2003;26:559–61.CrossRefGoogle Scholar
  6. 6.
    Brembilla-Perrot B, Brembilla A, Moulin-Zinsch A, Sellal JM, Olivier A, Manenti V, et al. Factors of negativity of electrophysiological study in children and teenagers complaining of tachycardia and prognostic significance. Pediatr Cardiol. 2015;36:64–70.CrossRefGoogle Scholar
  7. 7.
    Mah DY, Sherwin ED, Alexander ME, Cecchin F, Abrams DJ, Walsh EP, et al. The electrophysiological characteristics of accessory pathways in pediatric patients with intermittent preexcitation. Pacing Clin Electrophysiol. 2013;36:1117–22.CrossRefGoogle Scholar
  8. 8.
    Brembilla-Perrot B, Pauriah M, Sellal JM, Zinzius PY, Schwartz J, de Chillou C, et al. Incidence and prognostic significance of spontaneous and inducible antidromic tachycardia. Europace. 2013;15:871–6.CrossRefGoogle Scholar
  9. 9.
    Mills MF, Motonaga KS, Trela A, Dubin AM, Avasarala K, Ceresnak SR. Is there a difference in tachycardia cycle length during SVT in children with AVRT and AVNRT? Pacing Clin Electrophysiol. 2016;39:1206–12.CrossRefGoogle Scholar
  10. 10.
    Emmel M, Sreeram N, Brockmeier K. Catheter ablation of junctional ectopic tachycardia in children, with preservation of atrioventricular conduction. Z Kardiol. 2005;94:280–6.CrossRefGoogle Scholar
  11. 11.
    Brembilla-Perrot B, Moulin-Zinsch A, Sellal JM, Schwartz J, Olivier A, Zinzius PY, et al. Impact of transesophageal electrophysiologic study to elucidate the mechanism of arrhythmia on children with supraventricular tachycardia and no preexcitation. Pediatr Cardiol. 2013;34:1695–702.CrossRefGoogle Scholar
  12. 12.
    Drago F, De Santis A, Grutter G, Silvetti MS. Transvenous cryothermal catheter ablation of re-entry circuit located near the atrioventricular junction in pediatric patients: efficacy, safety, and midterm follow-up. J Am Coll Cardiol. 2005;45:1096–103.CrossRefGoogle Scholar
  13. 13.
    Ko JK, Ryu SJ, Ban JE, Kim YH, Park IS. Use of transesophageal atrial pacing for documentation of arrhythmias suspected in infants and children. Jpn Heart J. 2004;45:63–72.CrossRefGoogle Scholar
  14. 14.
    Law IH, Fischbach PS, Goldberg C, Mosca RS, Bove EL, Lloyd TR, et al. Inducibility of intra-atrial reentrant tachycardia after the first two stages of the Fontan sequence. J Am Coll Cardiol. 2001;37:231–7.CrossRefGoogle Scholar
  15. 15.
    Shih HT, Miles WM, Klein LS, Hubbard JE, Zipes DP. Multiple accessory pathways in the permanent form of junctional reciprocating tachycardia. Am J Cardiol. 1994;73:361–7.CrossRefGoogle Scholar
  16. 16.
    Kleinman ME, Chameides L, Schexnayder SM, Samson RA, Hazinski MF, Atkins DL, et al. Part 14: pediatric advanced life support: 2010 American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care. Circulation. 2010;122:S876–908.CrossRefGoogle Scholar
  17. 17.
    American Heart Association. 2005 American Heart Association (AHA) guidelines for cardiopulmonary resuscitation (CPR) and emergency cardiovascular care (ECC) of pediatric and neonatal patients: pediatric advanced life support. Pediatrics. 2006;117:e1005–28.CrossRefGoogle Scholar
  18. 18.
    Jones P, Peters MJ, Pinto da Costa N, Kurth T, Alberti C, Kessous K, et al. Atropine for critical care intubation in a cohort of 264 children and reduced mortality unrelated to effects on bradycardia. PLoS One. 2013;8:e57478.CrossRefGoogle Scholar
  19. 19.
    Pihlajamäki K, Kanto J, Aaltonen L, Iisalo E, Jaakkola P. Pharmacokinetics of atropine in children. Int J Clin Pharmacol Ther Toxicol. 1986;24:236–9.PubMedGoogle Scholar
  20. 20.
    Unna KR, Glaser K, Lipton E, Patterson PR. Dosage of drugs in infants and children. I. Atropine. Pediatrics. 1950;6:197–207.PubMedGoogle Scholar
  21. 21.
    Marcus B, Gillette PC, Garson A Jr. Electrophysiologic evaluation of sinus node dysfunction in postoperative children and young adults utilizing combined autonomic blockade. Clin Cardiol. 1991;14:33–40.CrossRefGoogle Scholar
  22. 22.
    Sileikiene R, Baksiene D, Sileikis V, Kazakavicius T, Vaskelyte J, Kevalas R. Changes in electrophysiologic properties of the conductive system of the heart in children with atrioventricular nodal reentrant tachycardia after 2-8 years following radiofrequency catheter ablation of the slow pathway. Medicina (Kaunas). 2009;45:632–8.CrossRefGoogle Scholar
  23. 23.
    Sledz J, Labus M, Mazij M. A simplified approach for evaluating sustained slow pathway conduction for diagnosis and treatment of atrioventricular nodal reentry tachycardia in children and adults. Adv Med Sci. 2018;63:249–56.CrossRefGoogle Scholar
  24. 24.
    Qureshi AU, Hyder SN, Sheikh AM, Sadiq M. Optimal dose of adenosine effective for supraventricular tachycardia in children. J Coll Physicians Surg Pak. 2012;22:648–51.PubMedGoogle Scholar
  25. 25.
    Sherwood MC, Lau KC, Sholler GF. Adenosine in the management of supraventricular tachycardia in children. J Paediatr Child Health. 1998;34:53–6.CrossRefGoogle Scholar
  26. 26.
    Díaz-Parra S, Sánchez-Yañez P, Zabala-Argüelles I, Picazo-Angelin B, Conejo-Muñoz L, Cuenca-Peiró V, et al. Use of adenosine in the treatment of supraventricular tachycardia in a pediatric emergency department. Pediatr Emerg Care. 2014;30:388–93.CrossRefGoogle Scholar
  27. 27.
    Till J, Shinebourne EA, Rigby ML, Clarke B, Ward DE, Rowland E. Efficacy and safety of adenosine in the treatment of supraventricular tachycardia in infants and children. Br Heart J. 1989;62:204–11.CrossRefGoogle Scholar
  28. 28.
    Losek JD, Endom E, Dietrich A, Stewart G, Zempsky W, Smith K. Adenosine and pediatric supraventricular tachycardia in the emergency department: multicenter study and review. Ann Emerg Med. 1999;33:185–91.CrossRefGoogle Scholar
  29. 29.
    Dixon J, Foster K, Wyllie J, Wren C. Guidelines and adenosine dosing in supraventricular tachycardia. Arch Dis Child. 2005;90:1190–1.CrossRefGoogle Scholar
  30. 30.
    Paul T, Pfammatter JP. Adenosine: an effective and safe antiarrhythmic drug in pediatrics. Pediatr Cardiol. 1997;18:118–26.CrossRefGoogle Scholar
  31. 31.
    Curtis AB, Belardinelli L, Woodart DA, Rown CS, Conti JB. Induction of atrioventricular node reentrant tachycardia with adenosine: differential effect of adenosine on fast and slow atrioventricular node pathways. JACC. 1997;30:1778–84.CrossRefGoogle Scholar
  32. 32.
    Johnson TN. The problem in scaling adult drug doses in children. Arch Dis Child. 2008;93:207–11.CrossRefGoogle Scholar
  33. 33.
    Lapage MJ, Walsh MJ, Reed JH, Saul JP. Adenosine mapping for adenosine-dependent accessory pathway ablation. Pacing Clin Electrophysiol. 2014;37:610–5.CrossRefGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2019

Authors and Affiliations

  • Nikola Krmek
    • 1
  1. 1.Department of PediatricsUniversity Clinical Hospital Center “Sestre Milosrdnice”ZagrebCroatia

Personalised recommendations